Standardization protocols and optimized precursor sets for the efficient application of automated parallel synthesis to lead optimization: A Mitsunobu example

被引:30
作者
Gentles, RG [1 ]
Wodka, D [1 ]
Park, DC [1 ]
Vasudevan, A [1 ]
机构
[1] Abbott Labs, Med Chem Technol, Dept R4CP, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
来源
JOURNAL OF COMBINATORIAL CHEMISTRY | 2002年 / 4卷 / 05期
关键词
D O I
10.1021/cc010090j
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
A strategy has been developed for the efficient application of automated parallel synthesis to specific aspects of the lead optimization processes employed in drug discovery. The method involves the synthesis of collections of compounds using sets of precursors designed to encompass established medicinal chemistry principles and that have been concurrently optimized with respect to a specific chemical transformation. The strategy is illustrated using an automated Mitsunobu protocol employing sets of aliphatic alcohols and phenols as precursors. The former has been formatted to perform simple alkyl homologation exercises, with the latter being designed for use in diversity-based studies.
引用
收藏
页码:442 / 456
页数:15
相关论文
共 34 条
[1]   METHOD FOR AUTOMATIC CLASSIFICATION OF CHEMICAL STRUCTURES [J].
ADAMSON, GW ;
BUSH, JA .
INFORMATION STORAGE AND RETRIEVAL, 1973, 9 (10) :561-568
[2]   Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship [J].
Andrews, CW ;
Bennett, L ;
Yu, LX .
PHARMACEUTICAL RESEARCH, 2000, 17 (06) :639-644
[3]  
AUSTEL V, 1984, STERIC EFFECTS DRUG, P8
[4]  
AUSTEL V, 1995, METH PRIN MED CHEM, V2, P49
[5]   Use of structure Activity data to compare structure-based clustering methods and descriptors for use in compound selection [J].
Brown, RD ;
Martin, YC .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1996, 36 (03) :572-584
[6]  
Cammish LE, 2000, PRACT APPROACH SER, V222, P277
[7]  
Craig P. N., 1980, BASIS MED CHEM, P331
[8]  
Davis AM, 1999, ANGEW CHEM INT EDIT, V38, P737, DOI 10.1002/(SICI)1521-3773(19990315)38:6<736::AID-ANIE736>3.0.CO
[9]  
2-R
[10]  
DEAN PM, 1999, MOL DIVERSITY DRUG D